First positive readout means nice bump and potential partnership...

First positive readout means nice bump and potential partnership in that interim before the 2nd readout, as there is more data than 7 people at that point. Proteinuria is definitely the easier of the two to achieve, and thankfully DXB is using a different MoA than Sparsentan. Guessing the 2nd readout to be late 2024 / early 2025.

There is some precedent for the GFR readout (2nd) should be it average. The FDA denied the fast track approval for Sparsentan and said to wait for the 2 year read out, which ultimately failed. Likely that DXB would be priced for failure at that point.